<DOC>
	<DOCNO>NCT01301911</DOCNO>
	<brief_summary>Cipatinib oral tyrosine kinase inhibitor target HER-1 HER-2 receptor . This study design evaluate safety tolerability cipatinib patient HER2 positive uncertain advance breast cancer : 1 . To evaluate safety tolerability cipatinib , maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) 2 . To determine pharmacokinetic profile cipatinib metabolites 3 . To assess preliminary antitumor activity 4 . To determine preliminary regimen phase II study 5 . To determine relation expression HER-1 HER-2 antitumor activity .</brief_summary>
	<brief_title>Study Cipatinib Patients With HER2 Positive Uncertain Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Aged ≥ 18 ≤ 65 year . ECOG performance status 0 1 . Life expectancy 3 month . Histologically cytologic confirm HER2 positive uncertain advance breast cancer curable available therapy . Screening laboratory value within follow parameter : ANC : ≥ 1.5 x 109/L Platelet count : ≥ 100 x 109/L Hemoglobin : ≥ 9.0 g/dL Serum albumin : ≥ 2.5 g/dL Total bilirubin : ≤ 1.5 x upper limit normal , ULN ALT AST : ≤ 1.5 x ULN Serum creatinine : ≤ 1.0 x ULN Creatinie clearnce rate : ≥ 50 mL/min Cholesterol≤7.75 mmol/L triglyceride≤2.5 x ULN LVEF : ≥ 50 % QTcF : &lt; 470 ms Recovery clinically significant AEs relate prior therapy . Duration late therapy 6 week nitroso mitomycin , 4 week operation , radiotherapy , cytotoxic agent molecular target . Ability willingness swallow tablet , dysfunction gastrointestinal absorption . All subject surgically sterile postmenopausal must agree commit use reliable method birth control duration study 6 month last dose test article . For woman child bear potential , negative urine serum pregnancy test result initiate cipatinib . Signed informed consent . Subjects third space fluid control drainage method . Steroid treatment 50 day , need longterm use steroid . Subjects uncontrol hypokalemia hypomagniesemia study entry . Subjects interrupt use drug may cause QT prolongation study . Subjects meningioma , active central nervous system metastasis indicate clinical symptom . Subjects liver metastasis ALT AST &gt; 1.5 x ULN . Treated treat EGFR HER2 TKIs study entry . Receiving antitumor therapy . Less 4 week last clinical trial . Pregnant breastfeed woman . Known history hypersensitivity cipatinib component . Ongoing infection ( determined investigator ) . Subjects heart disease : coronary artery disease , arrhythmia need treat , heart failure , LVEF &lt; 50 % , heart disease determine unfit study investigator , etc . Evidence significant medical illness investigator 's judgment substantially increase risk associate subject 's participation completion study . Examples include , limited , hypertension , severe diabetes , thyroid disease . Known history neurological psychiatric disease , include epilepsy dementia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast cancer , Advanced</keyword>
	<keyword>Cipatinib</keyword>
	<keyword>phase I</keyword>
	<keyword>HER2 positive uncertain advance breast cancer</keyword>
</DOC>